CD276 and breast carcinoma: Research indicates that in breast cancer, B7H3 expression impedes the proliferation of CD4+ and CD8+ T cells by diminishing the phosphorylation of the mammalian target of rapamycin (mTOR), thereby curtailing the release of IFN-γ.